CCA
MIST icon

Catalyst Capital Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Catalyst Capital Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-500
Closed -$9K – 377
2019
Q3 		$9K Hold
500
– – ﹤0.01% 348
2019
Q2 		$14K Buy
+500
New +$10.3K ﹤0.01% 291

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Catalyst Capital Advisors's MIST Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Milestone Pharmaceuticals (MIST) in Q4 2019, closing a stake of 500 shares — an estimated $9K sold.

Catalyst Capital Advisors first reported a position in MIST in Q2 2019 and held it in 2 quarters. The position peaked at $14K in Q2 2019. 25 funds tracked by Wall St. Rank hold MIST as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Milestone Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 500 Milestone Pharmaceuticals shares in Q4 2019, an estimated $9K.
  • Catalyst Capital Advisors first reported a position in Milestone Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Catalyst Capital Advisors's Milestone Pharmaceuticals position peaked at $14K in Q2 2019.
  • 25 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.